PD-1/PD-L1抑制剂相关的内分泌紊乱及其治疗的研究进展

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment

摘要: 免疫检查点治疗是肿瘤治疗的新模式，目前国内外已有多种免疫检查点单抗药物即程序性细胞死亡蛋白-1（PD-1）及其配体（PD-L1）抑制剂获批进入临床，在恶性黑色素瘤、肺癌、膀胱癌、淋巴瘤等多种肿瘤中得到了广泛应用，但随着PD-1/PD-L1抑制剂在临床上的逐步推广应用，其引起的各种免疫相关不良反应引起了广泛关注，特别是近年来国内外均有多个内分泌腺体受损的相关不良反应报道。本文对PD-1/PD-L1抑制剂治疗引起的各内分泌腺体相关不良反应研究现状以及对应临床处理方法作一综述。

Abstract: Immune checkpoint therapy is a new mode of tumor therapy. At present, many kinds of PD-1/PD-L1 inhibitors have been approved for clinical application on various tumors, such as malignant melanoma, lung cancer, bladder cancer, lymphoma, etc. However, with the gradual promotion and application in clinical practice, various immune-related adverse reactions caused by PD-1/PD-L1 inhibitors have attracted extensive attention. Especially in recent years, a number of adverse reactions related to endocrine gland injury have been reported. This paper reviews the research status and corresponding clinical treatment methods of endocrine gland related adverse reactions caused by PD-1/PD-L1 inhibitors.